What Is FGF9? Definition and What Research Reports

Plain definition

FGF9 stands for fibroblast growth factor 9. It is a secreted signalling protein — one member of the fibroblast growth factor (FGF) family — that is made by cells in a tissue, released into the surrounding space, and then binds fibroblast growth factor receptors (FGFRs) on the surface of neighbouring cells to change how those cells grow, differentiate or survive. In short, FGF9 is a paracrine growth factor: a protein that cells use to talk to the cells immediately around them. The term "FGF9" is used interchangeably for the gene (FGF9 in humans, Fgf9 in mice) and for the protein product, and context usually makes clear which is meant.

What class of molecule is it, and where does it come from?

FGF9 is a protein, not a short synthetic research peptide. That distinction matters when the term shows up in peptide-adjacent literature: unlike a 5–40 amino acid sequence made by solid-phase synthesis, FGF9 is a full-length secreted polypeptide that is normally produced by the body's own cells and is generally produced recombinantly for laboratory work. It belongs to the FGF9 subfamily alongside FGF16 and FGF20, which share sequence similarity and receptor preferences.

Sources and signalling partners studied in the literature include bone, where researchers described FGF9–FGFR2 signalling operating between osteocytes and preosteoblasts during mechanically driven intramembranous bone formation in an underdeveloped maxilla model (PMID 40913526), and the developing lung, where an Fgf9–Nolz1–Wnt2 axis was reported to regulate lung morphogenesis (PMID 37497597). Work in the cerebellum reported that FGF9 was required for Purkinje cell development and function (PMID 38352230), which is consistent with the broader picture of FGF9 as a developmental signalling molecule present across multiple organ systems rather than one tissue.

How the term is used in research

In published work, "FGF9" appears in three recurring roles:

• As an endogenous signal that is deleted, reduced or mutated. Studies knock out or mutate the gene and observe what changes. For example, a point-mutation model reported that Fgf9 (Y162C) altered information processing and social memory in mice (PMID 28695538).
• As a recombinant protein applied to cells or animals. Here FGF9 is added to a culture or model system to see what the added signal does — for instance, researchers reported that FGF9 treatment reduced off-target chondrocytes in iPSC-derived kidney organoids (PMID 40885721).
• As a downstream node in a regulatory network. Much of the recent literature positions FGF9 as the target of an upstream regulator, such as the report that USF1-activated hsa_circ_0076691 induced oxaliplatin resistance by facilitating FGF9 expression in a miR-589-3p-dependent manner (PMID 40529209).

None of these uses describes FGF9 as a consumer product. It is handled in the literature as a laboratory reagent and a biological signalling molecule, and the studies below are preclinical — cell culture, organoids and rodents.

What the published literature reports

The findings split roughly into tissue-protective observations and growth-promoting observations, and both appear in the same literature.

Metabolic and cardiac models

In a diabetic cardiomyopathy model, the study reported that FGF9 alleviated the cardiomyopathy phenotype in mice by activating Nrf2 through the SQSTM1/p62–Keap1 axis (PMID 41291247). In liver work, researchers reported that FGF9 alleviated a fatty liver phenotype by regulating hepatic lipid metabolism (PMID 35517790).

Kidney

A 2025 report described reduced FGF9 leading to kidney injury through effects on renal tubular epithelial cell epithelial–mesenchymal transition in diabetes (PMID 40977522). Separately, in a tissue-engineering context rather than a disease model, FGF9 treatment was reported to reduce off-target chondrocyte populations arising in iPSC-derived kidney organoids (PMID 40885721).

Bone and development

The maxilla study reported that FGF9–FGFR2 signalling between osteocytes and preosteoblasts mediated mechanotransduction-driven intramembranous osteogenesis (PMID 40913526). Developmental studies reported roles in lung morphogenesis via an Fgf9–Nolz1–Wnt2 axis (PMID 37497597) and in cerebellar Purkinje cell development and function (PMID 38352230).

Neurobehavioural

The Fgf9 (Y162C) mouse mutation study reported altered information processing and social memory relative to controls (PMID 28695538), one of the few behavioural datasets attached to this gene.

Tumour biology and other safety signals: What Studies Report

A substantial share of the FGF9 literature concerns proliferation and cancer, which is the main counterweight to the protective findings above. Because FGF9 is a growth factor, several papers examined what happens when it is elevated.

• Researchers reported that FGF9 promoted cell proliferation and tumorigenesis in TM3 mouse Leydig progenitor cells (PMID 36628285).
• A separate study reported an anti-cancer effect of cordycepin on FGF9-induced testicular tumorigenesis, using FGF9 as the tumour-driving stimulus (PMID 33172093).
• In colorectal chemoresistance work, the study reported that a circular RNA drove oxaliplatin resistance by facilitating FGF9 expression through miR-589-3p (PMID 40529209).
• A cervical cancer paper reporting that miR-187 inhibited cervical cancer cell growth by targeting FGF9 has since been retracted and should be read with that status in mind (PMID 37732515).

These reports are observations from cell lines and animal models about what elevated or targeted FGF9 did in those systems; they are not statements about what happens in people. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or before making any health decision.

At-a-glance summary of reported contexts

How to read this entry

Three limitations are worth holding onto. First, the FGF9 evidence base is preclinical: rodents, organoids and cell lines, not controlled human trials. Second, direction of effect is tissue-dependent — the same molecule was reported as protective in cardiac and hepatic models (PMID 41291247) and as proliferation-driving in testicular tumour models (PMID 36628285), so generalising from one organ to another is not supported. Third, at least one FGF9 paper in the indexed literature carries a retraction notice (PMID 37732515), a reminder to check publication status before relying on any single result. This entry is definitional and descriptive; it summarises what researchers reported and makes no recommendation about use of any substance.

References

• FGF9-FGFR2 Signaling via Osteocytes-Preosteoblasts Crosstalks to Mediate Mechanotransduction-Driven Intramembranous Osteogenesis in the Underdeveloped Maxilla (Advanced Science, 2025)
• FGF9 alleviates diabetic cardiomyopathy by activating Nrf2 via SQSTM1/p62-Keap1 in mice (Communications Biology, 2025)
• USF1-activated hsa_circ_0076691 induces oxaliplatin resistance via facilitating FGF9 expression in miR-589-3p-dependent manners (Non-coding RNA Research, 2025)
• FGF9 treatment reduces off-target chondrocytes from iPSC-derived kidney organoids (NPJ Regenerative Medicine, 2025)
• Fgf9 (Y162C) Mutation Alters Information Processing and Social Memory in Mice (Molecular Neurobiology, 2018)
• Reduced FGF9 Leads to Kidney Injury Through Regulating Renal Tubular Epithelial Cell EMT in Diabetes (Journal of Cellular and Molecular Medicine, 2025)
• FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism (Frontiers in Pharmacology, 2022)
• The Fgf9-Nolz1-Wnt2 axis regulates morphogenesis of the lung (Development, 2023)
• FGF9 is required for Purkinje cell development and function in the cerebellum (iScience, 2024)
• Anti-Cancer Effect of Cordycepin on FGF9-Induced Testicular Tumorigenesis (International Journal of Molecular Sciences, 2020)
• FGF9 promotes cell proliferation and tumorigenesis in TM3 mouse Leydig progenitor cells (American Journal of Cancer Research, 2022)
• [Retracted] miR-187 inhibits the growth of cervical cancer cells by targeting FGF9 (Oncology Reports, 2023)